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Accelerated Death Benefits, Viatical Settlements, 
and Viatical Loans: Options for the Terminally III 
Paula Schmidt* 
Abstract t 
There are three options available for terminally ill insureds who are inter-
ested in accessing all or part of the face value of their life insurance policies: 
through the life insurance company (accelerated death benefits), through a vi-
atical company (a via tical settlement), or through a via tical loan company (a 
via tical loan). This paper explores the definitions and tax regulations, calcula-
tions, and the claims process associated with accelerated death benefits and 
via tical settlements and loans. 
Key words and phrases: life expectancy, claims, taxes, regulations 
1 Introduction 
For a person diagnosed with a terminal illness, there are few mon-
etary options available to pay the expenses needed to sustain his or 
her life. Medical insurance may only cover expenses up to a limit, and 
their savings and/or possessions may not be enough to cover bills. For 
the insured terminally ill, however, there are often three other options: 
accelerated death benefits, viatical settlements, or via tical loans. 
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Accelerated death benefits are benefits offered by life insurance com-
panies to terminally ill insureds. The proceeds from an acceleration 
result from a recalculation of the insured's life expectancy due to the 
terminal illness and can be excluded from the owner's personal gross 
income under current tax law. The proceeds consist of a fraction (typi-
cally 50 percent, but can vary from 25 percent to 100 percent depending 
on the company) of the policy's face value, the remainder being paid at 
the time of death. There is sometimes a waiver of premiums during the 
period the insured is expected to die. If the insured survives the period, 
there may be a resumption of premiums. Whether the premium needs 
to be resumed is company specific and is stated in the policy or rider 
form that contains the accelerated benefit provision. 
The risk insurance companies take when they fund accelerated death 
benefits differs from the risk insurance companies assume at the sale 
of a life insurance policy. There is minimal adverse mortality risk in-
volved in accelerated death benefits, if the physician's diagnosis is cor-
rect, given the likelihood of death occurring in the near future. Thus, 
the risk assumed is primarily an investment risk. 
A viatical settlement is one in which the owner of a life insurance 
policy sells the policy to a viatical company for an amount less than the 
face amount. The amount paid is directly related to the amount of time 
the insured is expected to live, Le., the longer the life expectancy, the 
less the amount paid. The viatical company in turn pays the remaining 
premiums needed to keep the policy in force. 
If the person lives longer than expected, viatical settlement compa-
nies will suffer a decrease in their investment return. Thus, viaticals 
risk losing some of their profit. If they are highly leveraged, this could 
be a large percent of that profit. 
A viatical loan involves a policyowner giving collateral assignment 
of his or her life insurance policy to a viaticalloan company. The loan is 
then repaid in full at the time of death of the insured. The premiums are 
paid by the viaticalloan company and are subtracted from the viatical 
loan amount in the initial computation. Often, a via tical loan allows the 
policyowner to receive more of the death benefit than an accelerated 
death benefit or viatical settlement. At the death of the insured, the 
balance of the death benefit is paid to beneficiaries. 
The benefit covered in this paper is the terminal illness-triggered 
benefit. To be eligible for this benefit, a physician must certify that 
death is imminent within a specified time period. This time period is 
usually six months to a year, though 24 months is the requirement in the 
Internal Revenue Code for a benefit to be treated in a manner similar to 
life insurance proceeds. Therefore, a terminal illness-triggered benefit 
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is any payment made from a life insurance policy while the insured is 
alive that results from recalculating the insured's life expectancy due 
to the terminal illness. 
2 Life Insurance Companies 
2.1 The Calcu lation of Accelerated Death Benefits 
There are two common methods used to calculate accelerated death 
benefits: discounting the face value (less any outstanding policy loans) 
of the policy or by taking a lien against the policy. Other methods are 
used, but they are not as acceptable to most life insurance companies. 
The discounting method requires the face value of the policy to be 
discounted by a factor related to current market rates (e.g., the u.s. Trea-
sury bill rate) and the length of the acceleration period. The amount 
paid is subtracted from the face amount of the policy, which results in 
a lower remaining death benefit. In some cases, companies waive the 
premium during acceleration. Some life insurance companies charge an 
administrative fee to cover the expenses of processing the acceleration. 
Typical fees range from $100 to $300. 
A simple example of discounting an accelerated death benefit fol-
lows. Assume a policy with a $100,000 face amount, a 60 percent ac-
celeration benefit, no loans, a company-implemented administrative fee 
of $200, and a Treasury bill rate of 8 percent. The insured is assumed to 
have a year to live. The amount to cover the interest on the accelerated 
portion is: 
$60,000 - ($60,000/1.08) = $4,444.44. 
Therefore the accelerated payment is: 
$60,000 - $200 - $4,444.44 = $55,355.56. 
The policy would remain in force with a $40,000 death benefit. 
In the lien method, the accelerated benefit is treated as a loan se-
cured by the policy. Once death occurs, the loan is reimbursed with 
interest from the entire death benefit. The difference between the lien 
method and a straight policy loan is that for the lien method, advances 
can exceed the contract's cash value. With a loan, however, the policy-
owner only is able to obtain an amount not higher than the cash value 
of the policy. 
Let us now look at a lien method example using the same scenario as 
for discounting, with the exception that the 8 percent Treasury bill rate 
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is assumed to be the loan rate and there is a $200 administrative fee. 
The policyowner would be loaned $59,800 ($60,000 - $200) now. The 
death benefit remaining, assumed to be paid in one year's time, would 
be: 
$100,000 - ($60,000 * 1.08) = $35,200. 
The difference between the total payments for the two methods is 
minimal (less than $400). With the discounting method a payment of 
$55,355.56 could be received now and $40,000 at death. The total pay-
ment would be $95,355.56. The lien method offers $59,800 now and 
$35,200 at death, a total of $95,000. The final deciding factors depend 
upon the options available from the individual's insurance company. 
Some companies only offer one of the options. The policyowner also 
must decide if he or she would benefit from more money at acceleration 
or at death. These decisions vary for each individual. 
2.2 Regulations and Tax Treatment of Life Insurance Pro-
ceeds 
When an accelerated death benefit is paid to a policyowner, the in-
surance company must send a statement illustrating the effect of the 
benefit on the face amount of the policy, the specified amount of the 
benefit, the accumulation account, the cash value, any loan balance, and 
what the future premiums (if any) will be (Adam, 1990). 
The National Association of Insurance Commissioners (NAIC) for-
mulated model insurance regulations to serve as a guide to accelerated 
death benefits. A disclosure required by the NAIC guideline l is a brief 
description of the benefit and definitions of the conditions or occur-
rences that triggered the benefit payment. No further conditions may 
be placed on the payment of accelerated benefits other than those spec-
ified initially in the policy or rider. 
Benefit payment options also are covered in the NAIC 1996 guide-
line. The insured has the option of receiving the accelerated benefit 
in a lump sum, in periodic payments for a fixed time, or in a fixed 
amount for an indefinite period of time. Some companies require that 
the accelerated benefit be taken as a lump sum, but most accommo-
date policyholder wishes. To receive the accelerated death benefit, the 
owner often is required by the insurance company to surrender all or 
part of his or her policyholder rights (Cruise, 1994). 
1 NAIC guidelines can be obtained by writing to the NAIC at: NAIC, 120 West 12th 
Street, Suite 1100, Kansas City MO 64105-1925, USA. 
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The introduction of accelerated death benefits in early 1990 resulted 
in the general public and some insurance companies being concerned 
about tax uncertainties and terminology. To alleviate these concerns, 
the Internal Revenue Service (IRS) and the NAIC established tax regu-
lations and model insurance regulations, respectively. On August 21, 
1996, President Clinton signed The Health Coverage Availability and 
Affordability Act of 1996 (HR 3101) clarifying the tax treatment of ac-
celerated death benefits. This act went into effect on January 1, 1997; 
(see Chodes, 1997). The sections of the Internal Revenue Code (IRC) 
that affect accelerated death benefits are Sections 72, 101, 7702, and 
7702A. The regulations are being amended; more changes may occur 
in the future. 
State-specific regulations are based upon model regulations enacted 
by the NAIC. The NAIC cannot force states or insurance companies to 
use model regulations. Because the NAIC is composed of each state's 
respective insurance commissioner, though, most states have adopted 
the regulations. 
Once the states accept regulations, insurance companies must com-
ply and alter their poliCies (if needed) in order to do business within 
each individual state. At first most states allowed accelerated death 
benefit recipients to be exempt from state income taxes, though recip-
ients may still have had to pay federal taxes (Blake, 1993). Because no-
body really knew if taxes were owed or not, the NAIC advised insurance 
companies to add a disclaimer suggesting the policyholder consult his 
or her tax advisor about the tax treatment of such a provision (Adam, 
1990). 
Under Section 7702 of the IRC, a life insurance contract is defined as 
any contract that is a life insurance contract under applicable law, but 
only if the contract meets the cash value accumulation test or meets the 
guideline premium requirement and falls within the cash value corridor. 
Whichever of these two tests a life insurance contract meets at incep-
tion also must be met after a change in the death benefit is recorded 
(Kraus, 1993). Therefore, a redetermination of values must occur after 
accelera tion. 
The tax treatment has always been a concern for those terminally 
ill and considering such benefits. Current regulations provide that ac-
celerated benefits will be considered as death benefits under Sections 
101(a) and 7702. Section 101 states that any amount of a death benefit 
received in a lump sum or otherwise paid by reason of death of the 
insured is not included in a person's gross income (Freeman and Mar-
cus, 1993). The Health Insurance Portability and Accountability Act of 
1996 redefined Section 101 (g). With its passage there are now two types 
110 Journal of Actuarial Practice, Vol. 5, No.1, 1997 
of accelerated death benefits (received after December 31, 1996) that 
are excludable from gross income. They are amounts received from 
a life insurance policy or from a viatical settlement company for the 
sale or assignment of a policy. The determining factor is that the in-
sured is terminally or chronically ill (Wolosky, 1996). The act defines 
being terminally ill as having 24 months or less to live. To be classed 
as chronically ill, the insured is not able to perform at least two of six 
listed daily activities (Christopher, 1997). This paper, however, will not 
cover chronic illness benefits in any depth. 
The definitions and regulations of the IRS and NAIC aim to clar-
ify the treatment of accelerated benefits. Most state insurance depart-
ments have adopted similar regulations, so the alterations necessary 
from state to state tend to be minimal. It is most probable that the tax 
laws and regulations will continue to change as the insurance industry 
becomes more experienced in accelerated benefits. For now, the pro-
ceeds from a qualifying acceleration can be received free from personal 
income tax. With this clarification, the insurance industry should no-
tice more terminally ill persons submitting claims for accelerated death 
benefits. 
2.3 The Claims Process for Accelerated Death Benefits 
The process for accelerating the payment of benefits on a life policy 
has many elements. Most companies require a minimum face amount to 
be carried on a policy, i.e., $100,000, before any claim for acceleration 
of the death benefit can occur. Fraudulent claims can be reduced by 
setting a limit to the amount of accelerated benefit a policyholder can 
receive. A minimum amount also may be set to avoid the relatively 
excessive administrative expenses in processing small claims. 
Specialized claim forms are required for acceleration. These forms 
must be comprehensive enough to encompass all aspects of the illness 
and the benefit payout. In addition, these forms should include verifi-
cation and certification from the insured's physician stating the date of 
diagnosis of the terminal illness, the extent of the insured's symptoms, 
the proposed treatments and their efficacy, and the expected life span 
of the insured. The insured also should be asked to complete a claim 
form to prevent fraud (Adam, 1990). 
When claims are made during the contestable period, special effort 
must be made to determine whether the illness was present at the in-
ception of the policy (Hitzeman, 1992). If the illness was present, it 
gives the insurance company a legal reason not to accelerate the death 
benefit. The insurer must verify that the policy is a valid contract and 
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was issued based upon correct and accurate information before it de-
termines whether the accelerated benefit is payable. 
The medical information required by the claim forms should provide 
adequate data for an initial investigation for the possible contestability 
of the payment. If the submitted information appears to be legitimate 
and satisfactory to the insurance company's medical board, the claim 
is processed and paid (Reimers, 1994). 
If the information appears to be false, an extensive investigation 
usually follows. Certain steps are recommended to protect insurance 
companies from fraud by policyholders and physicians. First, compa-
nies must verify the attending physician's credentials. The next step is 
to obtain treatment records from any attending physicians and hospi-
tals. It also may be beneficial to interview the insured and/or spouse to 
determine the extent and severity of the illness and to rule out the pos-
sibility of self-inflicted injuries as the cause of the terminal condition. 
The policyholder must be asked if he or she is mentally competent and 
be determined as such (Hitzeman, 1992). Anything that seems suspi-
cious should be investigated to safeguard the insurance company. 
The insurance company should reserve its right to reaffirm the diag-
nosis of terminal illness by the company's medical doctor. Most compa-
nies also state within their rider or policy that if the insured's physician 
disagrees with the company's physician on the diagnosis, the company 
will pay a third impartial physician to perform an evaluation. Both 
parties should agree the third diagnOSis will be the one by which the 
insured and the company will abide (Hitzeman, 1992). 
Because claims only can be made by the policyowner, irrevocable 
beneficiaries and assignees can complicate the claim process. If a re-
lease cannot be obtained from either of these two, payment of the ad-
vanced benefit should be refused (Adam, 1990). In most cases the ben-
eficiaries are close to the insured and are aware of the ramifications of 
acceleration. Irrevocable beneficiaries and assignees commonly playa 
large role in the decision to accelerate. 
Companies offering such riders must be fair to all parties so they are 
not accused of taking advantage of the insured and the terminal con-
dition. At the same time the company must make correct assumptions 
about the premiums and/or fees charged so that they do not lose money 
offering such a benefit. Discrimination must not exist in the underwrit-
ing and processing of different types of terminal illnesses (Adam, 1990). 
The insurance company also must protect the privacy of the insured. 
No matter how careful and methodical an insurance company is in 
investigating claims, problems will arise. One problem is how to deal 
with an insured who recovers after receiving the accelerated death ben-
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efit. A correctly written policy should protect both parties in such an 
event (Adam, 1990). Some companies require an insured to resume 
payment of premiums on the face amount remaining after acceleration 
if the insured survives beyond the acceleration period (Aerts, 1994). 
Other companies waive the premium. 
Another possible problem is an insured who commits suicide after 
receiving his or her accelerated death benefit. If the suicide occurs 
within the customary two year contestability period the policy would be 
terminated; beneficiaries may have to repay the advance (Adam, 1990). 
If suicide occurs after the contestable period beneficiaries may receive 
the remaining death benefit. Each company must decide its stand on 
suicides. 
Claims practices of insurance companies are complicated by accel-
erated death benefits. In the past an insured died and a benefit was 
paid. Now an insured may have a terminal illness, and a partial bene-
fit may be paid. Insurance companies should expect more claims in a 
wider variety and greater volume due to terminal conditions. 
Accelerated death benefits are consumer friendly and possess a hu-
manitarian appeal that complements traditional life insurance (Wang, 
1990). This benefit promises an extra measure of financial security in 
the event of a catastrophic or terminal illness. Life insurance products 
have come to offer more while persons are alive instead of after they 
have died. Accelerated death benefits are one way companies are of-
fering their policyholders additional safeguards and personal benefits. 
This benefit allows companies a slight marketing advantage. Acceler-
ated benefits give the company's agents a selling point that is visible 
and desirable for insureds. It is seen by some agents to be a low risk, 
but a low reward provision. 
Although some controversy surrounds accelerated death benefits, 
most persons familiar with the concept praise it. The benefit may be re-
ceived as a lump sum, in installments, or as expenses are incurred. Pay-
ment depends upon the insurance company and its established prac-
tices. The payment can be a way for a dying person to take care of 
medical bills, visit family in a different part of the world, or do what 
he or she always has dreamed. The adverse impact of an accelerated 
death benefit is the decrease in the death benefit of the policy to the 
insured's survivors. 
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3 Viatical Companies 
3.1 Viatical Settlements 
There is a second option available to an insured whose insurance 
company does not offer accelerated death benefits or to an insured who 
wants an advance payment sooner than the insurance company offers. 
This option is to sell the life insurance policy to a viatical company. 
A viatical settlement is a private transaction in which a policyowner 
sells the policy while the insured is living. The owner sells the policy 
to a viatical company for an amount less than the face value of the 
policy. Viaticals usually offer a contract under which the company is 
designated as the sole benefiCiary of the life insurance policy. Most of 
these contracts are made with insureds who are terminally ill or have a 
catastrophic illness. Via tical companies expect to make their profits by 
buying life insurance policies from terminally ill insureds. 
The factors that determine the purchase price (Le., the amount of 
payment offered) are based on the amount of the policy's death benefit, 
the terminally ill insured's life expectancy, the annual premium, the 
type of policy, the rating of the insurance company, and the market 
rate available on a similar investment. Some companies may buy partial 
benefits in which the policyholder names a co-benefiCiary who retains 
an interest in the death benefit. 
The purchase price, however, hinges on life expectancy-the more 
time a person has to live, the less money the policyowner will receive 
(Kristof, 1991). The key is evaluating an insured's life expectancy (Bar-
rett, 1992). The sooner the insured dies, the sooner the viatical com-
pany receives the death benefit and its profit. This may sound inhu-
mane [some have called viatical settlements death futures (Niedzielski, 
1995)], but those selling the poliCies see the viatical option as a chance 
to do something with part of the death benefit (Sing, 1990). 
The policy sale process starts when the viatical company verifies 
the life expectancy of the insured and computes a purchase price. The 
owner can accept or reject the offer. If the policyowner rejects the 
viatical company's initial purchase price, the viatical company often 
returns to its investors and tries to improve its offer to one that is 
more acceptable to the policyowner. Viatical companies are third-party 
competitors in the free market. They try to offer the best possible price 
to policyowners (Faig, 1997). 
After buying the policy, the viatical company assumes the premium 
payment and either becomes the sole beneficiary or a co-beneficiary of 
the policy. At the time of death of the insured the viatical company 
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collects the portion of the death benefit to which it is entitled. Thus 
via tical companies require a large amount of upfront capital and have 
no immediate payoff. 
3.2 Regulations and Tax Treatment of Viatical Settlement 
Proceeds 
The via tical industry began in 1989 with three companies. Currently 
there are 54 viatical settlement companies operating nationwide (Con-
nolly, 1995b). The entire viatical industry is estimated to have had a 
market of $400 million in policies purchased in 1994 and $500 million 
in 1995, with the potential to reach $6 billion within the next five years 
(Connolly, 1995a). As an industry they have established themselves as 
an organized secondary market in the life insurance arena (Faig, 1997). 
A growing concern is whether state insurance departments should 
regulate viatical companies. Although viaticals are not insurance com-
panies, they cross into the realm of the insurance industry. They are 
purchasing policies involving mortality risk. A viatical company has the 
option and ability to pay persons who have up to five years to live (which 
is the void in the insurance industry that viatical companies fill) (Stone, 
1993). Only settlements based on two years or less life expectancy, 
however, could be received tax free. 
The Health Insurance Portability and Accountability Act of 1996 now 
defines terminally ill as having 24 months or less to live. A stipulation in 
the 1996 act is that in order for a viatical settlement to be considered 
to be tax-free, the viatical company must be licensed by the state. If 
that state does not have a licensing system the viatical must pay to the 
policyowner at least the minimum in purchase price (see Table 1) for 
policies as set by the NAIC viatical model act. The regulations do allow 
viaticals to decide the length of life expectancy in which they will invest 
and if they will pay more than these minimum required prices. 
The percentages in Table 1 may be reduced 5 percent for viaticating 
a policy written by an insurer rated less than the highest four cate-
gories by A.M. Best. This percentage reduction could be alleviated by 
the existence of state guarantee associations which would lessen the 
bankruptcy risk of the less favorably rated companies. 
Though the number of persons wanting to sell their life insurance 
policies to viaticals is relatively low, it continues to rise each year. Limits 
to acceleration and the possibility for a high return mean that investors 
are eager to buy viator policies. Insurance regulators and insurance 
companies are concerned, however, that viatical companies may be-
come a problem for the insurance industry. Moral risk has been cited 
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Table 1 
NAIC Model Minimum Purchase Price As a Percentage of Policy Face Value 
Life Expectancy Months Minimum (In Months) Percentage 
<6 
6-12 
12-18 
18-24 
24+ 
80% 
70% 
65% 
60% 
50% 
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as a major factor in the regulation of via tical companies. It has been considered by some that the via tical industry has been created by com-panies waiting for a financial reward that is greatly increased by the early death of an insured (Faig, 1997). Via tical companies tend to believe they are dealing with the sale of a private asset that should not concern the NAIC. The viatical industry also was under attack by the Securities and Exchange Commission (SEC) from August 1995 until July 1996. The SEC considered viatical settle-ments to be securities and challenged their validity in the U.S. court system (Connolly, 1995a). The SEC wanted viaticals to register the frac-tionalized shares of life insurance polices they were selling to investors. Many of the via tical settlement companies disliked this because it in-fringed on the small investors who could only afford to purchase shares of policies and not entire ones. 
The District of Columbia Court of Appeals ruled in July 1996 that viatical settlements are not securities and are not to be considered in-surance policies either (Connolly, 1996). The court held that " ... a vi-atical settlement is not an insurance policy, and the business of selling fractional interests in insurance policies is no part of the business of insurance" (Connolly, 1996). The court reasoned that profits from such viatical settlements do not come from the efforts of a party other than the investors themselves. The SEC may appeal this ruling. The via ticals see the legislation and regulations as hindrances to their business. Regulation also may affect the selling price of policies. With increased costs due to registration fees and expenses incurred because of required compliance, the amount an insured would receive would decrease. In the end, legislation and regulations could hurt the persons regulators are trying to help. 
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companies, viaticals, and the general public) will lead to more stability 
in the accelerated benefits industry. 
Medical advances will be a significant factor in the future of acceler-
ated death benefits for many reasons. First, with further developments 
and enhancements of DNA and genetic testing, the diagnosis of the pos-
sibility of being stricken with a terminal illness at some point of time in 
the future will become more accurate. Second, the enhanced treatment 
of and/or cures for current diseases will reduce the severity of terminal 
illness. These two reasons may make the calculation of life expectan-
cies more difficult, however, as has been the example of AIDS protease 
inhibitors. These inhibitors have greatly increase the life expectancy 
of some patients while they have not had much of an effect on others. 
Even though these are beneficial advances, such new-found methods 
may cause uncertainty among those calculating life expectancies. 
Eventually, increased accuracy in calculating life expectancy and 
more readily available advanced treatment methods will lead to more 
exact accelerated death benefit payments. The final payout, however, 
will be based on who calculates the life expectancy, what formula is 
used, and who has made the final terminal diagnosis. When the final 
payout is made because of decisions of a handful of persons, the result 
can make or break a terminally ill insured and could be construed as 
morally unjust. Using a simple equation may allow difficult decisions 
to be minimized by simplistic assumptions for mortality and interest. 
If the time between payout and death can be determined, the dollar 
investment necessary to cover the difference between the accelerated 
portion and the actual will be more accurately calculated. This is an 
advantage to all parties and would reduce the risk and profit margins. 
Not only can the insurance and viatical companies cover any losses 
while also making a profit, but insureds also should receive the best 
price for the policy. 
The path of accelerated death benefits and viatical settlement com-
panies will continue in the same direction, but the company field will 
narrow. Only those viaticals that are strong in their investment port-
folios and keep up to date with medical advances will remain in the 
accelerated death benefit market. In the future viaticals also may buy 
life insurance policies from healthy but old persons. 
Steven Arenson, a vice president of Viaticus, Inc., painted a picture 
of the current viatical market. In Employee Benefit Plan Review (1996) 
Mr. Arenson was quoted as saying, "Only 2% of the terminally ill are 
AIDS patients, but 95% of those early viatical settlements (mid-1980's) 
involved AIDS victims. Last year (1995), 23% of our viatical settlements 
involved cancer patients." This represents the shift in the viatical mar-
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ket from one almost entirely serving AIDS patients to expanding to 
other illnesses. 
Some of the unsettled issues are: 
• Whether the use of the accelerated benefit proceeds can be re-
stricted (Pear, 1992); What happens if the insured lives longer than 
the stipulated length for the acceleration; and 
• What effects the accelerated benefits will have on a person's eligi-
bility for governmental assistance (Will it be considered an asset?) 
(Employee Benefit Plan Review, 1990). 
Additional questions arise from beneficiaries over estate tax and es-
tate/inheritance tax treatment of the death benefit remaining after ac-
celeration. Because of these and other issues, some insurance compa-
nies have been waiting to initiate and introduce accelerated benefits. 
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